Immune response to L2 guinea pig leukemia-specific antigens.
Strain 2 guinea pigs were immunized with the LE-L2C cell line and challenged with either LE-L2C or BZ-L2C, a subline of L2C leukemia deficient in la gene product and C3 receptor. The LE-L2C-immune animals were completely protected from a challenge of 5 X 10(6) cells (100 times the lethal dose) of either cell line, and the delayed skin test responses for both lines of injected cells were equivalent. Thus established in vivo immune recognition of the leukemia antigen was similar for both cell lines. After repeated immunization of strain 2 animals with BZ-L2C cells, animals were challenged with 3 X 10(5) viable cells; 9 of 13 animals survived. A subsequent 5 x 10 (6) challenge lowered survival to 8 of the 13 animals. The skin test response to BZ-L2C developed slowly during the immunization period, but survivors of the viable cell challenge exhibited good responses to skin testing with BZ-L2C or LE-L2C leukemic cells. Thus the BZ-L2C cell line possesses a leukemia-specific antigen, but the immunogenicity of this mutant line is decreased when compared to that of the LE-L2C line.
D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage; D002460:Cell Line; D005260:Female; D006168:Guinea Pigs; D006968:Hypersensitivity, Delayed; D007109:Immunity; D007942:Leukemia, Experimental / Q000276:immunology*; D008297:Male; D009368:Neoplasm Transplantation; D012882:Skin Tests; D014184:Transplantation, Homologous
D000951:Antigens, Neoplasm